Venous Thromboembolism Pipeline

DelveInsight’s, “Venous Thromboembolism- Pipeline Insight, 2025” report provides comprehensive insights about 10+ companies and 10+ pipeline drugs in Venous Thromboembolism pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

 

Geography Covered

• Global coverage

 

Venous Thromboembolism: Understanding

Venous Thromboembolism: Overview

Venous Thromboembolism (VTE) is a blood clot that blocks the flow of blood through veins. A VTE can be stuck in the deep veins of the legs or arms (deep vein thrombosis) or travel through the veins to the lungs (pulmonary embolism). A VTE that blocks the lungs is life-threatening. It is the third most common cardiovascular disease worldwide and is the most common avoidable cause of hospital death. VTE encompasses two conditions: deep vein thrombosis (DVT) and pulmonary embolism (PE). DVT is a blood clot that forms in the veins that lie deep within the muscles, for example in the leg or pelvis. If all or part of the DVT breaks off and the blood clot moves to block a vessel in the lungs, this is known as a PE, an event which can be rapidly fatal.

Symptoms of DVT include: pain, swelling, redness of the affected area, usually the leg and the skin may also be warm to the touch. Symptoms of PE include: acute shortness of breath, chest pain, rapid heart rate, and   rapid breathing some people may also cough blood.

Different tests are used to diagnose DVT and PE. Tests to diagnose DVT includes Blood tests called a D-dimer test measures levels of a substance that is released when blood clots dissolve and Vascular ultrasound this noninvasive imaging test is usually the first choice for visualizing the veins and the flow of blood through them. MR venography MRI can be more reliable than ultrasound for examining pelvis, abdomen and chest. It uses pulses of radio-frequency waves to detect blood clots. Contrast venography this traditional X-ray test requires a contrast dye to be injected into vein to make it show up in images. It’s more invasive than other imaging tests, but it is considered more accurate and may be used if other tests are inconclusive.

Venous thromboembolism treatment options vary depending on how threatening the clot is. Some DVTs may be managed with oral medications, while some PEs may need to be urgently removed. The doctor might remove a life-threatening PE through a catheter in the vein, or they might inject a medication called a thrombolytic that dissolves the clot quickly because of possible complications, though, these interventions are reserved for emergencies. When a VTE is not life-threatening, treatment focuses on preventing existing clots from getting bigger and new clots from forming. Preventative treatments include anticoagulants (blood thinners) that reduce clotting and compression stockings that encourage circulation.

 

"Venous Thromboembolism- Pipeline Insight, 2025" report by DelveInsight outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Venous Thromboembolism pipeline landscape is provided which includes the disease overview and Venous Thromboembolism treatment guidelines. The assessment part of the report embraces, in depth Venous Thromboembolism commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Venous Thromboembolism collaborations, licensing, mergers and acquisition, funding, designations and other product related details.

 

Report Highlights

• The companies and academics are working to assess challenges and seek opportunities that could influence Venous Thromboembolism R&D. The therapies under development are focused on novel approaches to treat/improve Venous Thromboembolism.

 

Venous Thromboembolism Emerging Drugs Chapters

This segment of the Venous Thromboembolism report encloses its detailed analysis of various drugs in different stages of clinical development, including phase III, II, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.

 

Venous Thromboembolism Emerging Drugs

• Abelacimab: Anthos Therapeutics, Inc.

Abelacimab is a highly selective, fully human monoclonal antibody with its novel dual activity against Factor XI and its activated form, XIa. This dual activity enables profound suppression of Factor XI activity and has the potential of hemostasis-sparing anticoagulation. The phase II study showed that Abelacimab was well tolerated with no safety signals the ability of drug to provide effective anticoagulation with a reduced rate of bleeding. Currently, the drug is in Phase III stage of its development for the treatment of Venous Thromboembolism.

Further product details are provided in the report……..

 

Venous Thromboembolism: Therapeutic Assessment

This segment of the report provides insights about the different Venous Thromboembolism drugs segregated based on following parameters that define the scope of the report, such as:

• Major  Players in Venous Thromboembolism
• There are approx. 10+ key companies which are developing the therapies for Venous Thromboembolism. The companies which have their Venous Thromboembolism drug candidates in the most advanced stage, i.e. phase III include, Anthos Therapeutics, Inc.

 

Phases

DelveInsight’s report covers around 10+ products under different phases of clinical development like

• Late stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I) along with the details of
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates

 

Route of Administration

Venous Thromboembolism pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

• Oral
• Intravenous
• Subcutaneous
• Parenteral
• Topical

 

Molecule Type

Products have been categorized under various Molecule types such as

• Recombinant fusion proteins
• Small molecule
• Monoclonal antibody
• Peptide
• Polymer
• Gene therapy

 

Product Type

Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.

 

Venous Thromboembolism: Pipeline Development Activities

The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Venous Thromboembolism therapeutic drugs key players involved in developing key drugs.

 

Pipeline Development Activities

The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Venous Thromboembolism drugs.

 

Venous Thromboembolism Report Insights

• Venous Thromboembolism Pipeline Analysis
• Therapeutic Assessment
• Unmet Needs
• Impact of Drugs

 

Venous Thromboembolism Report Assessment

• Pipeline Product Profiles
• Therapeutic Assessment
• Pipeline Assessment
• Inactive drugs assessment
• Unmet Needs

 

Key Questions

Current Treatment Scenario and Emerging Therapies:

• How many companies are developing Venous Thromboembolism drugs?
• How many Venous Thromboembolism drugs are developed by each company?
• How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Venous Thromboembolism?
• What are the key collaborations (Industry–Industry, Industry–Academia), Mergers and acquisitions, licensing activities related to the Venous Thromboembolism therapeutics?
• What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
• What are the clinical studies going on for Venous Thromboembolism and their status?
• What are the key designations that have been granted to the emerging drugs?

Stay Updated with us for new articles @ Latest DelveInsight Blogs